CARDIOVASCULAR JOURNAL OF AFRICA • Vol 23, No 3, April 2012
152
AFRICA
concentric LV remodelling increased. Neither clinic systolic/
diastolic nor 24-hour systolic/diastolic BP control accounted
for these residual changes. Twenty-four-hour and day PP
were associated with residual LV structural changes. These
findings suggest that optimal therapeutic strategies for reducing
cardiovascular risk in hypertensives of African ancestry have yet
to be achieved. Further studies are required to evaluate whether
reducing PP to acceptable target levels would improve the
capacity to reverse LV structural abnormalities.
This work was supported by an open educational grant from Bayer. GRN and
AJW are supported by the Medical Research Council of South Africa, the
Circulatory Disorders Research Trust, the University Research Council of the
University of the Witwatersrand, and the South African National Foundation
for Research.
References
1.
Levy D, Salomon M, D’Agostino RB, Belanger AJ, Kannel WB.
Prognostic implications of baseline electrocardiographic features and
their serial changes in subjects with left ventricular hypertrophy.
Circulation
1994;
90
: 1786–1793.
2.
Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS,
Snapinn S,
et al
. Regression of electrocardiographic left ventricular
hypertrophy during antihypertensive treatment and the prediction of
major cardiovascular events.
J Am Med Assoc
2004;
292
: 2343–2349.
3.
Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS,
Papademetriou V,
et al
. Prognostic significance of left ventricular mass
change during treatment of hypertension.
J Am Med Assoc
2004;
292
:
2350–2356.
4.
Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG,
Saba PS,
et al.
Patterns of left ventricular hypertrophy and geometric
remodeling in essential hypertension.
J Am Coll Cardiol
1992;
19
:
1550–1558.
5.
Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation
of left ventricular mass and geometry to morbidity and mortality in
uncomplicated essential hypertension.
Ann Intern Med
1991;
114
:
345–352.
6.
Gerdts E, Cramariuc D, de Simone G, Wachtell K, Dahlöf B, Devereux
RB. Impact of left ventricular geometry on prognosis in hypertensive
patients with left ventricular hypertrophy (the LIFE study).
Eur J
Echocardiogr
2008;
9
: 809–815.
7.
Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S,
et
al
. Left ventricular concentric geometry during treatment adversely
affects cardiovascular prognosis in hypertensive patients.
Hypertension
2004;
43
: 731–738.
8.
Bluemke DA, Kronmal RA, Lima JAC, Olson J, Liu K, Burke GL,
et al.
The relationship of left ventricular mass and geometry to incident cardi-
ovascular events. The MESA (Multi-Ethnic Study of Atherosclerosis)
Study.
J Am Coll Cardiol
2008;
52
: 2148–2155.
9.
Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M,
et al.
Prognostic implications of left ventricular mass and geometry following
myocardial infarction: the VALIANT (VALsartan in Acute myocardial
iNfarcTion) Echocardiographic Study.
J Am Coll Cardiol (Cardiovasc
Imaging)
2008;
1
: 582–591.
10. Eguchi K, Ishikawa J, Hoshide S, Ishikawa S, Pickering TG, Schwartz
JE,
et al.
Differential impact of left ventricular mass and relative wall
thickness on cardiovascular prognosis in diabetic and nondiabetic
hypertensive subjects.
Am Heart J
2007;
154
: 79.e9–15.
11. Milani RV, Lavie CJ, Mandeep R, Mehra MR, Ventura HO, Kurtz JD,
et
al.
Left ventricular geometry and survival in patients with normal left
ventricular ejection fraction.
Am J Cardiol
2006;
97
: 959–963.
12. Lavie CJ, Milani RV, Ventura HO, Messerli FH. Left ventricular geom-
etry and mortality in patients > 70 years of age with normal ejection
fraction.
Am J Cardiol
2006;
98
: 1396–1399.
13. Wachtell K, Dahlöf B, Rokkedal J, Papademetriou V, Nieminen MS,
Smith G,
et al
. Change of left ventricular geometry pattern after 1
year of antihypertensive treatment: The Losartan Intervention for
Endpoint reduction in hypertension (LIFE) Study.
Am Heart J
2002;
144
: 1057–1064
.
14. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-
Rosei E,
et al
. On behalf of the CATCH investigators. Comparative
effects of candesartan and enalapril on left ventricular hypertrophy in
patients with essential hypertension: the candesartan assessment in the
treatment of cardiac hypertrophy (CATCH) study.
J Hypertens
2002;
20
: 2293–2300.
15. Heesen WF, Beltman FW, Smit AJ, May JF, de Graeff PA, Muntinga
JHJ, Havinga TK, Schuurman FH, van der Veur E, Meyboom-de
Jong B, Lie KI. Reversal of pathophysiologic changes with long-term
lisinopril treatment in isolated systolic hypertension.
J Cardiovasc
Pharmacol
2001;
37
: 512–521.
16. Taniguchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M,
et al.
Effects of spironolactone during angiotensin II receptor blocker treat-
ment on the left ventricular mass reduction in hypertensive patients
with concentric left ventricular hypertrophy.
Circ J
2006;
70
: 995–1000.
17. Grandi AM, Solbiati F, Laurita E, Maresca AM, Nicolini E, Marchesi
C,
et al
. Effects of dual blockade of Renin-Angiotensin system on
concentric left ventricular hypertrophy in essential hypertension:
a Randomized, Controlled Pilot study.
Am J Hypertens
2008;
21
:
231–237.
18. Cuspidi C, Meani S, Valerio C, Fusi V, Sala C, Maisaidi M, Zanchetti A.
Effects of Angiotensin II receptor blockade-based therapy with losartan
on left ventricular hypertrophy and geometry in previously treated
hypertensive patients.
Blood Press
2006;
15
: 107–115.
19. Bleumink GS, Deinum J, Mosterd A, Witteman JC, Hofman A, Stricker
BH. Antihypertensive treatment is associated with improved left
ventricular geometry: the Rotterdam Study.
Pharmacoepidemiol Drug
Saf
2004;
13
: 703–709.
20. Agabiti-Rosei E, Ambrosioni E, Dal Palu C, Muiesan ML, Zanchetti A
on behalf of the RACE Study Group. ACE inhibitor ramipril is more
effective than the
β
-blocker atenolol in reducing left ventricular mass
in hypertension. Results of the RACE (ramipril cadioprotective evalua-
tion) study.
J Hypertens
1995;
13
: 1325–1334.
21. Kizer JR, Arnett DK, Bella JN, Paranicas M, Rao DC, Province MA,
et al
. Differences in left ventricular structure between black and white
hypertensive adults. The Hypertension Genetic Epidemiolgy Network
Study.
Hypertension
2004;
43
: 1182–1188.
22. Skudicky D, Sareli P, Libhaber E, Candy G, Radevski I, Valtchanova Z,
et al
. Relationship between treatment-induced changes in left ventricu-
lar mass and blood pressure in black African hypertensive patients.
Results of the Baragwanath Trial.
Circulation
2002;
105
: 830–836.
23. Sareli P, Radevski IV, Valtchanova ZP, Libhaber E, Candy GP, Den
Hond E,
et al.
Efficacy of different drug classes used to initiate antihy-
pertensive treatment in black subjects: results of a randomized trial in
Johannesburg.
Arch Intern Med
2001;
161
: 965–971.
24. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regard-
ing quantitation in M-mode echocardiography: results of a survey of
echocardiographic measurement.
Circulation
1978;
58
: 1072–1083.
25. Nunez E, Arnett DK, Benjamin EJ, Liebson PR, Skelton TN, Taylor
H,
et al
. Optimal threshold value for left ventricular hypertrophy in
blacks: the Atherosclerosis Risk in Communities Study.
Hypertension
2005;
45
: 58–63.
26. Woodiwiss AJ, Libhaber CD, Majane OHI, Libhaber E, Maseko M,
Norton GR. Obesity promotes left ventricular concentric rather than
eccentric geometric remodeling and hypertrophy independent of blood
pressure.
Am J Hypertens
2008;
21
: 1144–1151.
